淋巴结微转移与子宫内膜癌的结局
这项多中心回顾性注册研究纳入428例子宫内膜癌患者,比较淋巴结阴性未接受辅助治疗者、淋巴结微转移接受辅助治疗者与淋巴结微转移未接受辅助治疗者的无病生存。中位随访84.8个月,微转移未辅助治疗者无病生存显著低于淋巴结阴性者,接受辅助治疗者与淋巴结阴性者相似。
要点
- 淋巴结微转移未接受辅助治疗者无病生存显著低于淋巴结阴性者(p=0.0001)。
- 微转移接受辅助治疗者中位无病生存与淋巴结阴性者相似(p=0.648)。
- 微转移者辅助治疗与疾病事件风险显著降低相关(HR 0.29,95%CI 0.13-0.65)。
核心结论
- 淋巴结微转移与子宫内膜癌患者无病生存降低相关。
- 辅助治疗与微转移患者无病生存改善相关。
研究设计与样本
- 多中心、回顾性、基于注册的研究,初始纳入2392例子宫内膜癌患者,排除后最终分析428例。
主要发现
- 最终研究纳入428例:302例(70.6%)为淋巴结阴性且未接受辅助治疗,95例(22.2%)为淋巴结微转移且接受辅助治疗,31例(7.2%)为淋巴结微转移且未接受辅助治疗。
- 中位随访84.8个月。
- 未接受辅助治疗时,微转移队列的无病生存较淋巴结阴性队列显著降低(p=0.0001)。
- 接受辅助治疗时,淋巴结微转移患者的中位无病生存与淋巴结阴性患者相似(p=0.648)。
- 微转移且未接受辅助治疗者与淋巴结阴性者相比,疾病事件的校正风险比为2.23(95%CI 1.26-3.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between nodal micrometastases and clinical outcome of endometrial cancer is unclear. PATIENTS AND METHODS: We performed a multicenter, retrospective registry-based study of 2392 patients with endometrial cancer with and without nodal micrometastases. The primary outcome measure was disease-free survival. RESULTS: After exclusions, the final study involved 428 patients: 302 (70.6%) with node-negative endometrial cancer, who did not receive adjuvant treatment, 95 (22.2%) with nodal micrometastases who received adjuvant treatment, and 31 (7.2%) with nodal micrometastases who did not receive adjuvant treatment. The median follow-up was 84.8 months. Without adjuvant therapy the disease-free survival in the cohort of patients with micrometastases was significantly reduced as compared with disease-free survival in the node-negative cohort (p = 0.0001). With adjuvant therapy the median disease-free survival of patients with nodal micrometastases was similar with those of node-negative patients (p = 0.648). The adjusted hazard ratio for disease events among patients with micrometastases and no adjuvant therapy, as compared with node-negative patients, was 2.23 (95% confidence interval [CI] 1.26-3.95). In the cohort with micrometastases the relative risk of events was significantly decreased by adjuvant therapy (HR 0.29, 95%CI 0.13-0.65) even after adjustment for age at diagnosis, myometrial invasion, histological grade and type, and performance status. CONCLUSIONS: Nodal micrometastases are associated with decreased disease-free survival of patients with endometrial cancer. Adjuvant therapy was associated with improved disease-free survival of patients with micrometastases.
引用
- Ignatov A, Lebius C, Ignatov T, et al. Lymph node micrometastases and outcome of endometrial cancer. Gynecol Oncol. 2019. PMID: 31345606. doi:10.1016/j.ygyno.2019.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。